{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:37:54Z","timestamp":1761647874641,"version":"3.44.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1053\/j.seminhematol.2011.03.008","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T03:34:50Z","timestamp":1311564890000},"page":"208-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of Elderly Patients With Mantle Cell Lymphoma"],"prefix":"10.1053","volume":"48","author":[{"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette K.","family":"Doorduijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2011.03.008_bib1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients","volume":"144","author":"'t Veer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3324\/haematol.2009.011759","article-title":"Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma","volume":"95","author":"Gressin","year":"2010","journal-title":"Haematology"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib3","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib4","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3324\/haematol.2010.025627","article-title":"Front-line treatment of mantle cell lymphoma","volume":"95","author":"Geisler","year":"2010","journal-title":"Haematology"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib5","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/asheducation-2009.1.542","article-title":"Current treatment standards and emerging strategies in mantle cell lymphoma","author":"Dreyling","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib7","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib8","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003805.pub2","article-title":"Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma","author":"Schulz","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11864-003-0023-x","article-title":"Mantle cell lymphoma: therapeutic strategies are different from CLL","volume":"4","author":"Hiddemann","year":"2003","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2000.18.4.773","article-title":"Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib12","first-page":"1002","article-title":"Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients","volume":"84","author":"Zinzani","year":"1999","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib14","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/blood.V116.21.373.373","volume":"116","author":"Rummel","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib16","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib17","first-page":"168","volume":"114","author":"Rummel","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)","volume":"132","author":"Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib20","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib21","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib23","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood.V116.21.2791.2791","article-title":"Final results of the RiPAD+C regimen including Velcade in front line therapy for elderly patients with mantle cell lymphoma","volume":"116","author":"Gressin","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2005.05777.x","article-title":"Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma","volume":"131","author":"Bauwens","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib29","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","article-title":"Limited-stage mantle-cell lymphoma","volume":"14","author":"Leitch","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib30","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","article-title":"Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group","volume":"16","author":"Hiddemann","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib31","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1995.13.11.2819","article-title":"Efficacy of four different regimens in 64 mantle cell lymphoma cases\u2014clinicopathological comparison with 498 other non-Hodgkin's lymphoma sybtypes\u2014EORTC Lymphoma Cooperative Group","volume":"13","author":"Teodorovic","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/oxfordjournals.annonc.a010568","article-title":"Involvement of the CCND1 gene in hairy cell leukemia","volume":"7","author":"Boer de","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib34","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fernandez","year":"2010","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib35","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib37","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","article-title":"A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma\u2014long-term results of a multicenter observation study","volume":"50","author":"Weigert","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib38","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood-2010-02-270538","article-title":"Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase II study","volume":"116","author":"Bethge","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib39","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1080\/10428190701618268","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma","volume":"48","author":"Rodriguez","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib40","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","article-title":"High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas","volume":"48","author":"Weide","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib41","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.25055","article-title":"Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma","volume":"116","author":"Ruan","year":"2010","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib42","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdl395","article-title":"Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma","volume":"18","author":"Morschhauser","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib43","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib44","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.008_bib45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdm463","article-title":"A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"19","author":"Morschhauser","year":"2008","journal-title":"Ann Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:12Z","timestamp":1758522072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196311000357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0037196311000357"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.03.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Elderly Patients With Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}